SI
JAZZ icon

Standard Investments’s Jazz Pharmaceuticals JAZZ Stock Holding History

Standard Investments’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,701
Closed -$299K – 87
2015
Q2 		$299K Buy
+1,701
New +$305K 0.02% 122
2014
Q2 		– Sell
-19,575
Closed -$2.71M – 185
2014
Q1 		$2.71M Buy
+19,575
New +$2.95M 0.25% 63

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Standard Investments's JAZZ Position: Q3 2015 in Review

Standard Investments sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2015, closing a stake of 1,701 shares — an estimated $299K sold.

Standard Investments first reported a position in JAZZ in Q1 2014 and held it in 2 quarters. The position peaked at $2.71M in Q1 2014. 360 funds tracked by Wall St. Rank hold JAZZ as of Q3 2015.

  • Standard Investments reported no remaining Jazz Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Standard Investments sold 1,701 Jazz Pharmaceuticals shares in Q3 2015, an estimated $299K.
  • Standard Investments first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Standard Investments's Jazz Pharmaceuticals position peaked at $2.71M in Q1 2014.
  • 360 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2015.

Based on Standard Investments's 13F filing for Q3 2015, filed 16 Nov 2015.